✓ Translated by DotMD AI Clinical Council Source: BJS open • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #33839747 ↗

Phase III Randomized Trial: Hepatocellular carcinoma progression during bridging before liver transplantation (N = 525)

Original Paper Title: “Hepatocellular carcinoma progression during bridging before liver transplantation”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 525
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Patients with HCCs within the MC that did not show tumour progression under locoregional therapy had the best outcomes after liver transplantation.
  • Study Design & Sample: Phase III Randomized Trial published in BJS open (N = 525 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in BJS open (2021), this phase iii randomized trial evaluating 525 human participants investigated: Recipient selection for liver transplantation in hepatocellular carcinoma (HCC) is based primarily on criteria affecting the chance of long-term success. Key clinical takeaway: Patients with HCCs within the MC that did not show tumour progression under locoregional therapy had the best outcomes after liver transplantation.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (BJS open, 2021-03-05; N = 525; Rigor 87/100): Patients with HCCs within the MC that did not show tumour progression under locoregional therapy had the best outcomes after liver transplantation.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: liver-transplantation → Condition: liver-disease-alcoholic → Condition: pancreatic-pseudocyst →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 33839747: Phase III Randomized Trial: Hepatocellular carcinoma progression during bridging before liver transplantation (N = 525)

3 of 3 Free Questions Remaining